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Ongoing and anticipated COVID-19 human challenge studies in the UK may advance our understanding of COVID-19 and
facilitate the licensure of safe, effective, and easily deployable next-generation COVID-19 vaccines and boosters. We argue
that international volunteer recruitment for COVID-19 human challenge trials can help promote diversity in these trials and
ensure a sufficient number of eligible volunteers, both of which will increase the benefits of challenge research. We explore
the ethical ramifications of dealing with unfair background conditions of global vaccine injustice to expand medical research,
and conclude that international recruitment for COVID-19 human challenge trials can be conducted ethically provided that
several robust protections are in place for volunteers.
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Background
The world’s first COVID-19 human challenge study, led by a
consortium of hVIVO, Imperial College London, and the UK
Vaccine Taskforce, began in March 2020. Several follow-up
studies are being planned or considered: the University of
Oxford has received ethics approval to conduct a reinfection
challenge study with up to 64 seropositive volunteers, and
researchers at the Leiden University Medical Center in the
Netherlands are preparing for the first COVID-19 challenge
study outside of the UK (University of Oxford, 2021;
Reuters, 2020). 
As SARS-CoV-2 virus variants are reshaping the COVID-19
pandemic, human challenge studies may be of significant
utility by yielding data on viral activity in the upper
respiratory tract, COVID-19 reinfection, and correlates of
immune protection (Medicines and Healthcare products
Regulatory Agency, 2021). Most importantly, challenge
studies can gauge the efficacy of boosters and
next-generation vaccines that may be needed to protect the
world against emerging virus variants, such as the Beta and
Delta variant (Rohrig and Eyal, 2021). This is especially
important for developing countries that are in need of rapid
next-generation vaccine authorization, since mRNA
vaccines— which have alone been shown to be effective
against the B.1.351 strain— have been overwhelmingly
prepurchased by wealthy countries and have proven difficult
to handle for LMICs due to their cold chain requirements
(Duke Global Health Innovation Center, 2021). Identifying a
correlate of immune protection would also expedite future
vaccine efficacy trials by enabling surrogate endpoints for
efficacy. 
However, because volunteer recruitment is only taking place
in the UK, COVID-19 human challenge studies may have
limited public health value. This is for two reasons. First,
UK-only recruitment means that COVID-19 human
challenge trial participants are not representative of global
genetic, environmental, behavioural, and microbiome
diversity. Not only is the UK not demographically reflective
of the world, but Black and Ethnic Minority (BAME)
populations are systematically underrepresented in British
medical research (Ijoyemi, 2021). We explore this limitation
in greater detail in subsection 2.1, Promoting Trial Diversity.
Second, UK-only recruitment may preclude an adequate
number of trial participants. Several challenge study designs
may require unvaccinated volunteers, which is a problem
since as of July 10th, 2021, over 88% of Britons have already
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received their first dose (Public Health England, 2021). This
may limit trials for next-generation vaccines, in which
volunteers will likely need to be seronegative before they are
exposed to the challenge agent, as well as COVID-19
reinfection studies like the one planned by the University of
Oxford, which needs to recruit unvaccinated volunteers to
control for the effect of previous vaccination on re-exposure
to the virus. 
As time passes, the share of eligible volunteers will continue
to decrease under the current schema. The UK has the
highest COVID-19 vaccine willingness rate in Europe—
91% as of June 2021 (YouGov, 2021). Those who elect not to
get vaccinated once vaccines are readily accessible are
presumably the least likely to partake in a COVID-19 human
challenge trial due to mistrust in the medical system. The
greatest population of eligible volunteers for COVID-19
human challenge trials will increasingly be found
internationally, and in low and middle income countries
(LMICs) in particular, where vaccination rates are extremely
low.
We argue below that international recruitment could improve
the value of the resultant challenge trial data and fulfill an
ethical obligation to promote global inclusion in medical
research. We consider some of the key protections that must
be put into place to ensure that international recruitment for
challenge trials is conducted ethically.
Ethical considerations for international recruitment
While allowing international recruitment of unvaccinated
volunteers may have significant public health value by
enabling COVID-19 human challenge studies to test boosters
and next-generation vaccines, such recruitment would likely
draw increased scrutiny from the global health research
community, mindful of the checkered history of the
profession that has been marked by exploitative and
extractive research practices (Washington, 2006).
We explore three unique ethical considerations presented by
expanding the inclusion criteria of ongoing and planned
COVID-19 human challenge trials in the UK to include
international volunteers, with a particular focus on
recruitment from LMICs, and conclude that with robust
protections in place for volunteers, these trials can remain
ethical.  
2.1 Promoting trial diversity. 
The imperative duty of ethicists reviewing challenge
proposals is to minimize risks to volunteers and maximize
the societal benefits of research. While international
challenge trial volunteer recruitment would affect both sides
of the risk-benefit analysis, we think that the benefits of
increased international diversity in COVID-19 human
challenge trials outweigh the risks, provided that this
recruitment includes robust protections for volunteers.
For young healthy volunteers, Manheim et al. find that the
risks of participating in a COVID-19 human challenge trial
are lower than other commonly acceptable medical
procedures such as living organ donation (Manheim et al.,
2021). Some evidence shows that BAME populations are at
greater risk of severe disease and death due to COVID-19;
however, the differences in risk are small relative to other
comorbidities (White, 2020). For instance, a 22-year-old
Black woman would be at lower risk in a COVID-19 human
challenge trial than a 29-year-old white man, holding other
comorbidities constant. 
On the other hand, the benefits of including BAME
volunteers in COVID-19 human challenge trials would be
significant. The lack of global volunteers from various ethnic
backgrounds in current COVID-19 challenge trials could
limit the generalizability of the resultant data (Kafuko, 2021).
This is especially problematic, since the data accrued from
challenge trials will have the most public value if they can be
used to support the authorization of vaccines in developing
countries. Given that efficacy and viral transmission data in
challenge trials is being inferred from a relatively small
challenge cohort, it is especially important for the sample to
include volunteers with diverse genetics and microbiomes, as
well as environmental and behavioural stressors (Hagan et
al., 2019). Notably, this is a reason for COVID-19 human
challenge trials to include volunteers both from wealthy
countries and LMICs to optimize for trial diversity, not to
include solely volunteers from LMICs. 
A final ethical argument in support of COVID-19 human
challenge trial diversity is an opposition to medical
paternalism and the obligation to foster global inclusion in
medical research. It seems contrary to the spirit of
equity-centered research to needlessly restrict volunteers
living in LMICs from exercising the opportunity to
voluntarily participate in the research and the development of
therapeutics which may be distributed to them in their host
countries19. Over 2,000 people from LMICs have expressed
interest in taking part in COVID-19 human challenge studies
with the non-profit 1Day Sooner. Giving people in LMICs
equal opportunity to partake in global research is respectful
of their agency as prospective research volunteers, and may
alleviate vaccine hesitancy and the suspicion of medical
institutions that exists in many BAME and LMIC
communities as a result of historical exploitation, exclusion
from research, and a lack of readily available information
about the vaccine development process among people in
LMICs (Hawkins and Emmanuel, 2008). International
recruitment of participants from LMICs also fulfills the
principle of justice: sharing of burdens and resultant benefits
between the rich countries and LMICs. 
2.2 Capitalizing on unfair background conditions
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International recruitment from LMICs is desired for human
challenge trials precisely because volunteers from LMICs are
disproportionately unvaccinated, a phenomenon that only
exists due to an unjust global vaccination scheme in which
rich countries have cornered the market for effective
vaccines. One may therefore worry that international
recruitment would be complicit with a morally impermissible
public health landscape on one hand, and damaging to
volunteers and host countries on the other by entrenching
structural inequalities in research capacity. 
While these concerns are well-founded, we argue that
international recruitment for COVID-19 human challenge
trials may be less exploitative than field efficacy trials to
gauge the efficacy of next-generation vaccines for three
reasons. We use the definition of exploitation provided by
Emmanuel et al., in which “A exploits B when B receives an
unfair level of benefits or unfair burden of risks as a result of
interacting with A” (Emmanuel et al., 2014).
Firstly, many LMICs have under resourced healthcare
systems, meaning that if someone becomes infected with
COVID-19, which may be inevitable due to low vaccination
rates, serious disease may go untreated. Oppositely, in human
challenge trials in the UK, participants would be offered the
highest quality care available globally in specially
constructed and staffed medical centers, at no monetary cost
to themselves.
Second, COVID-19 challenge trials last only a couple of
weeks for trial participants (Imperial College London, 2021),
whereas field trials can last several months, and in some
cases could require volunteers to withhold receiving
authorized vaccines to ensure efficacy results. 
Third, challenge trials only require around one hundred trial
participants to gauge vaccine efficacy against infection,
whereas field trials may require tens of thousands of
participants, creating a far larger research burden for
involved communities.
Further protections to minimize exploitation are ethically
necessary, as the COVID-19 pandemic has seen problematic
dynamics between researchers in developed countries and
potential trial participants in LMICs, in which developing
countries bore the costs of research without receiving the
benefits. For instance, researchers at the University of
Oxford moved part of their Phase III vaccine study to South
Africa and Brazil in mid-2020, where COVID-19
transmission was greater, to expedite efficacy results after
transmission waned in the UK. The Oxford vaccine was
ultimately of little use in South Africa due to the prevalence
of the B.1.351 strain, meaning that South Africans bore the
costs of research without receiving any of the benefits. If it
was not for the B.1.351 variant, South Africa could have
benefitted from the trial by, for example, getting preferential
treatment during allocations of the resultant vaccine.
In the context of human challenge trials, if volunteers did not
receive a vaccine in the trial, all trial volunteers should be
offered an authorized COVID-19 vaccine at the completion
of the trial to protect their safety thereafter. As is the case
with ongoing challenge studies, high-quality, cost-free
medical care must be available for international volunteers in
the case of any adverse events.
The primary justification of COVID-19 challenge research is
to speed the approval of next-generation vaccine candidates
and boosters, many of which are well-suited for distribution
and application in LMICs, where the current authorized
vaccines that have been overwhelmingly prepurchased by
wealthy countries are limited and in some cases not
accessible. Conditioning the ethical approval of the trial on
guaranteeing a certain share of vaccine delivery resulting
from the research to LMICs would ensure that the benefits of
research are shared in earnest by volunteer host countries.
The informed consent procedures for the trial must be
monitored by an independent entity from LMICs to
guarantee that trial participants fully understand the risks of
the trial. Advocates from LMICs must also be available to
represent volunteers during the course of the study. Lastly, in
contrast to the ongoing COVID-19 human challenge study in
London, the protocol for international recruitment and
challenge study design should be made public before the first
volunteer is recruited to ensure transparency and
accountability.
2.3 Volunteer Payment
Payment for participation in medical and pharmaceutical
research, including challenge studies that recruit volunteers
from endemic settings are particularly controversial. There is
a live debate amongst bioethicists about which framework
for determining monetary incentives should be used, and
which view of the distinctions between different types of
payments is most appropriate (Ndebele et al., 2008;
Fernandez-Lynch et al., 2021). 
One novel ethical consideration presented by these challenge
trials is whether research participants from LMICs should
receive equal compensation as participants from developed
countries in the same trial. These trials may be the first
instance when international research participants will be
transported to a single site to participate alongside one
another, rather than research happening simultaneously
across multiple locales. It would be egregious if two
participants from different countries, doing the same “work”,
in the same place and at the same time, were to receive
significantly different amounts of money on the basis that
they are citizens of different countries. While this
consideration should be duly weighed against legitimate
concerns about exercising undue influence over people in
LMICs through compensation, we agree with
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Blumenthal-Barby and Ubel that underpayment is a greater
concern than overpayment for COVID-19 human challenge
studies (Blumenthal-Barby and Ubel, 2020). 
Perhaps the most unique circumstance surrounding the
existing COVID-19 challenge trials with respects to worries
about undue financial inducement is the fact that more than
2,000 people from LMICs have already volunteered to
participate in COVID-19 challenge trials without any
expectation of financial gain with the non-profit 1Day
Sooner. Whether or not these volunteers are ultimately
eligible for a challenge trial, we should view this as evidence
that there are many young people from a diversity of LMICs
who have good faith altruistic intentions when it comes to
contributing to this research (1Day Sooner, 2021).
Conclusion
Next-generation vaccines are likely necessary to end the
COVID-19 pandemic worldwide, and human challenge trials
may be a key step toward trialing vaccine candidates.
Recruiting international volunteers for COVID-19 human
challenge studies in the UK can improve these trials both
scientifically and ethically by increasing trial diversity and
solving for a possible lack of volunteers.
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